Health supervision for children with neurofibromatosis

Pediatrics

Volumn 121, Issue 3, 2008, Pages 633-642

  Hersh, Joseph H ^a  

^a NONE

Author keywords

, neurofibroma; Cafe au lait spots; Neurofibromatosis; Neurofibromatosis 1; Optic glioma

Indexed keywords

DNA;

ADOLESCENT; ADULT; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; BIRTH CONTROL; BLOOD PRESSURE MEASUREMENT; BONE DYSPLASIA; BONE RADIOGRAPHY; CAFE AU LAIT SPOT; CHILD; CHILD DEVELOPMENT; CHILD GROWTH; CHILDHOOD DISEASE; CHROMOSOME 17; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DNA DETERMINATION; EARLY DIAGNOSIS; FAMILY COUNSELING; FAMILY HISTORY; GENE MUTATION; GENETIC COUNSELING; HAMARTOMA; HUMAN; HYPERTENSION; INFANT; IRIS TUMOR; MALIGNANT TRANSFORMATION; MENTAL DEFICIENCY; NEUROFIBROMATOSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE GLIOMA; PATIENT MONITORING; PERIODIC MEDICAL EXAMINATION; PERIPHERAL NERVE TUMOR; PRACTICE GUIDELINE; PREGNANCY; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; SKIN MANIFESTATION; SPEECH DISORDER; DISEASE COURSE; FEMALE; HEALTH STATUS; HOSPITALIZATION; LONG TERM CARE; MALE; METHODOLOGY; MONITORING; MORTALITY; MULTIMODALITY CANCER THERAPY; NEWBORN; PEDIATRICS; PHYSIOLOGY; PRESCHOOL CHILD; REVIEW; RISK ASSESSMENT; SICKNESS IMPACT PROFILE; SURVIVAL RATE; TREATMENT OUTCOME;

CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HEALTH STATUS; HUMANS; INFANT; INFANT, NEWBORN; LONG-TERM CARE; MALE; MONITORING, PHYSIOLOGIC; NEUROFIBROMATOSIS 1; PEDIATRICS; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 40949132576     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-3364     Document Type: Article

References (48)

1. Dunn DW. Neurofibromatosis in childhood. Curr Probl Pediatr. 1987;17(8):445-497
2. Huson SM. Recent developments in the diagnosis and management of neurofibromatosis. Arch Dis Child. 1989:64(5):745-749
3. Huson SM, Hughes RAC, eds. The Neurofibromatoses: A Pathogenetic and Clinical Overview. London, England: Chapman and Hall; 1994
4. Listernick R, Charrow J. Neurofibromatosis type 1 in childhood. J Pediatr. 1990;1 16(6):845-853
5. Obringer AC, Meadows AT, Zackai EH. The diagnosis of neurofibromatosis-1 in the child under the age of 6 years. Am J Dis Child. 1989;143(6):717-719
6. Riccardi VM. Type 1 neurofibromatosis and the pediatric patient. Curr Probl Pediatr. 1992;22(2):66-106
7. Friedman JM, Riccardi VM. Clinical and epidemiologic features. In: Friedman JM, Gutmann DH, MacCollin M, Riccardi VM, eds. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. 3rd ed. Baltimore, MD: Johns Hopkins University Press; 1999:29-86
8. Rubenstein AE, Korf BR, eds. Neurofibromatosis: A Handbook for Patients, Families and Health-Care Professionals. New York, NY: Thieme Medical Publishers; 1990
9. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278(l):51-57
10. North KN. Neurofibromatosis 1 in childhood. Semin Pediatr Neurol. 1998;5(4):231-242
11. Crowe FW, Schull WJ, Neel JV. A Clinical, Pathological, and Genetic Study of Multiple Neurofibromatosis. Springfield, 1L: Charles C. Thomas; 1956
12. Viskochil D. Neurofibromatosis type 1. In: Cassidy SB, Allan-son JE, eds. Management of Genetic Syndromes. Hoboken, NJ: John Wiley & Sons Inc;2005:369-384
13. National Institutes of Health Consensus Development Conference statement: neurofibromatosis. Bethesda, Md, USA, July 13-15, 1987. Neurofibromatosis. 1988;1(3):172-178
14. DeBella K, Szudek J, Friedman JM. Use of National Institutes of Health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 2000;105(3 pt 1):608-614
15. Korf BR. Diagnostic outcome in children with multiple cafe au lait spots. Pediatrics. 1992;90(6):924-927
16. Huson SM, Compston DA, Clark P, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in South East Wales.
17. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet. 1989;26(11):704-711
18. Stevenson DA, Birch PH, Friedman JM, et al. Descriptive analysis of tibial pseudoarthrosis in patients with neurofibromatosis 1. Am J Med Genet. 1999;84(5):41 3-419
19. Listernick R, Charrow J, Greenwald MJ, Esterly NB. Optic gliomas in children with neurofibromatosis type 1. J Pediatr. 1989;114(5):788-792
20. Listernick R, Louis DN, Packer RJ, Gutmann DH. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol. 1997;41 (2):143-149
21. Blazo MA, Lewis RA, Chintagumpala MM, Frazier M, McCluggage C, Plon SE. Outcomes of systemic screening for optic pathway tumors in children with neurofibromatosis type 1. Am J Med Genet. 2004;127(3):224-229
22. Laue L, Comite F, Hench K, Loriaux DL, Cutler GB Jr, Pescovitz OH. Precocious puberty associated with neurofibromatosis and optic gliomas: treatment with luteinizing hormone releasing hormone analogue. Am J Dis Child. 1985:139(11):1097-1100
23. Listernick R, Charrow J. Knowledge without truth: screening for complications of neurofibromatosis type 1 in childhood. Am J Med Genet. 2004;127:221-223
24. Listernick R, Ferner RE, Liu GT, Gutman DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol. 2007;61 (3):189-198
25. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve tumors in neurofibromatosis 1. J Med Genet. 2002;39(5):311-314
26. Knight WA III, Murphy WK, Gottlieb JA. Neurofibromatosis associated with malignant neurofibromas. Arch Dermatol. 1973;107(5):747-750
27. Hope DG, Mulvihill JJ. Malignancy in neurofibromatosis. Adv Neurol. 1981;29:33-56
28. Clementi M, Milani S, Mammi I, Boni S, Monciotti C, Tenconi R. Neurofibromatosis type 1 growth charts. Am J Med Genet. 1999;87(4):317-323
29. Riccardi VM. Skeletal system. In: Friedman JM, Gutmann DH, MacCollin M, Riccardi VM, eds. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. 3rd ed. Baltimore, MD: Johns Hopkins University Press; 1999:205-273
30. Fuller CE, Williams GT. Gastrointestinal manifestations of type 1 neurofibromatosis (von Recklinghausen's disease). Histopathology. 1991;19( 1):1-11
31. Rudolph CD, Hyman PE, Altschuler SM, et al. Diagnosis and treatment of chronic intestinal pseudo-obstruction in children: report of consensus workshop. J Pediatr Gastroenterol Nutr. 1997;24(1):102-112
32. Colby RS, Saul RA. Is Jaffe-Campanacci syndrome just a manifestation of neurofibromatosis type 1? Am J Med Genet A. 2003;123(l):60-63
33. Kuorilehto T, Poyhonen M, Bloigu R, Heikkinen J, Vaananen K, Peltonen J. Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int. 2005;16(8):928-936
34. North KN, Riccardi V, Samango-Sprouse C, et al. Cognitive function and academic performance in neurofibromatosis 1: consensus statement from the NF1 Cognitive Disorders Task Force. Neurology. 1997;48(4):112]-1127
35. Gutmann DH. Learning disabilities in neurofibromatosis 1: sizing up the brain. Arch Neurol. 1999;56(11):1322-1323
36. Eldridge R, Denckla MB, Bien E, et al. Neurofibromatosis type 1 (Recklinghausen's disease): neurologic and cognitive assessment with sibling controls. Am J Dis Child. 1989;143(7):833-837
37. Hofman KJ, Harris EL, Bryan RN, Denckla MB. Neurofibromatosis type 1: the cognitive phenotype. J Pediatr. 1994;124(4):S1-S8
38. Saal HM, Schorry EK, Hopkin RJ. Nasal speech and velopharyngeal dysfunction: a neglected feature of neurofibormatosis-1. Proc Greenwood Genetic Cent. 2004;23:94-95
39. Carey JC, Laub JH, Hall BD. Penetrance and variability in neurofibromatosis: a genetic study of 60 families. Birth Defects Orig Artic Ser. 1979;15(5B):271-281
40. Barker D, Wright E, Nguyen K, et al. Gene for von Recklinghausen neurofibromatosis is in the pericentric region of chromosome 17. Science. 1987;236(4805):1100-1102
41. Fountain JW, Wallace MW, Brereton AM, et al. Physical mapping of the von Recklinghausen neurofibromatosis region on chromosome 17. Am J Hum Genet. 1989;44(l):58-67
42. Ledbetter DH, Rich DC, O'Connell P, Leppert M, Carey JC. Precise localization of NF1 to 17q 11.2 by balanced translocation. Am J Hum Genet. 1989;44(l):20-24
43. Gutmann DH, Collins FS. The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron. 1993;10(3):335-343
44. Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001;104(4):593-604
45. Messiaen LM, Callens T, Mortier G, et al. Exhaustive mutation analysis of the NF1 gene allows the identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat. 2000;15(6):541-555
46. Korf BR, Schneider G, Young Poussaint TY. Structural anomalies revealed by neuro-imaging studies in the brains of patients with neurofibromatosis type 1 and large deletions. Genet Med. 1999;1(4):136-140
47. Blickstein I, Lancet M, Shoham Z. The obstetric perspective of neurofibromatosis. Am J Obstet Gynecol. 1988;158(2):385-388
48. Weissman A, Jakobi P, Zaidise J, Drugan A. Neurofibromatosis and pregnancy: an update. J Re-prod Med. 1993;38(11):890-896